Compare Snowflake Inc (SNOW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs TG Therapeutics Inc — how do they compare? Snowflake Inc trades at $271.42 (market cap $95.09B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: Snowflake Inc is far larger — about 11.5× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| SNOW | TGTX | |
|---|---|---|
Market Cap | $95.09B | $8.26B |
Sector | Technology | Health |
52-Week High | $280.16 | $59.06 |
52-Week Low | $121.11 | $26.39 |
Enterprise Value | $94.90B | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
